Following on from information provided to NICE by the company in February 2020, the appraisal of Nivolumab in combination with ipilimumab for untreated metastatic non-small-cell lung cancer [ID1675] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1675 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2020, the appraisal of Nivolumab in combination with ipilimumab for untreated metastatic non-small-cell lung cancer [ID1675] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 04 February 2020 | The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of nivolumab in combination with ipilimumab for untreated metastatic non-small-cell lung cancer ID1675. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. However, the company that markets nivolumab and ipilimumab has advised NICE that they are no longer pursuing a licence in the UK for these products for this indication. In light of this information NICE will not be progressing with the scoping and appraisal exercise and consequently the scope consultation will be closed early. If you have any comments or concerns please contact the project manager for this proposed appraisal Emily Richards on 44 (0)161 413 4070 or via email on emily.richards@nice.org.uk |
| 04 February 2020 | Suspended. Company no longer pursuing a license in the UK |
| 18 December 2019 | In progress. Referred December 5 2017 |
For further information on our processes and methods, please see our CHTE processes and methods manual